Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-marketing safety survey of Opdivo in pediatric recurrent or refractory classical Hodgkin lymphoma
jRCT2031240473Recruiting
- Sponsor
- Ono Pharmaceutical
- Start
- Sep 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of nivolumab in classical Hodgkin lymphoma (cHL), sponsored by Ono Pharmaceutical. Primary endpoints: Safety: occurrence of adverse drug reactions and infections and Safety: adverse events. Started Sep 2021; status: recruiting.
02
Drugs
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on jRCT2031240473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240473.